Targeted therapy for soft tissue sarcomas in adolescents and young adults
Diana A Steppan, Christine A Pratilas, David M Loeb Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors originating from the mesenchyme...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-03-01
|
Series: | Adolescent Health, Medicine and Therapeutics |
Subjects: | |
Online Access: | https://www.dovepress.com/targeted-therapy-for-soft-tissue-sarcomas-in-adolescents-and-young-adu-peer-reviewed-article-AHMT |
id |
doaj-a1241be507b94a359737e933f6e837f4 |
---|---|
record_format |
Article |
spelling |
doaj-a1241be507b94a359737e933f6e837f42020-11-24T20:59:22ZengDove Medical PressAdolescent Health, Medicine and Therapeutics1179-318X2017-03-01Volume 8415532127Targeted therapy for soft tissue sarcomas in adolescents and young adultsSteppan DAPratilas CALoeb DMDiana A Steppan, Christine A Pratilas, David M Loeb Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors originating from the mesenchyme. Even though they affect individuals in all age groups, the prevalence of subtypes of STSs changes significantly from childhood through adolescence into adulthood. The mainstay of therapy is surgery, with or without the addition of chemotherapy and/or radiation therapy. These treatment modalities are associated, in many cases, with significant morbidity and, given the heterogeneity of tumor histologies encompassed by the term “STS”, have not uniformly improved outcomes. Moreover, some subgroups of STSs appear to be more, and others less, responsive to conventional chemotherapy agents. Over the last two decades, our understanding of the biology of STSs is slowly increasing, allowing for the development of more targeted therapies. We review the new treatment modalities that have been tested on patients with STSs, with a special focus on adolescents and young adults, a group of patients that is often underrepresented in clinical trials and has not received the dedicated attention it deserves, given the significant differences in biology and treatment response in comparison to children and adults. Keywords: synovial sarcoma, MPNST, soft tissue sarcoma, targeted therapyhttps://www.dovepress.com/targeted-therapy-for-soft-tissue-sarcomas-in-adolescents-and-young-adu-peer-reviewed-article-AHMTsynovial sarcomaMPNSTsoft tissue sarcomatargeted therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Steppan DA Pratilas CA Loeb DM |
spellingShingle |
Steppan DA Pratilas CA Loeb DM Targeted therapy for soft tissue sarcomas in adolescents and young adults Adolescent Health, Medicine and Therapeutics synovial sarcoma MPNST soft tissue sarcoma targeted therapy |
author_facet |
Steppan DA Pratilas CA Loeb DM |
author_sort |
Steppan DA |
title |
Targeted therapy for soft tissue sarcomas in adolescents and young adults |
title_short |
Targeted therapy for soft tissue sarcomas in adolescents and young adults |
title_full |
Targeted therapy for soft tissue sarcomas in adolescents and young adults |
title_fullStr |
Targeted therapy for soft tissue sarcomas in adolescents and young adults |
title_full_unstemmed |
Targeted therapy for soft tissue sarcomas in adolescents and young adults |
title_sort |
targeted therapy for soft tissue sarcomas in adolescents and young adults |
publisher |
Dove Medical Press |
series |
Adolescent Health, Medicine and Therapeutics |
issn |
1179-318X |
publishDate |
2017-03-01 |
description |
Diana A Steppan, Christine A Pratilas, David M Loeb Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors originating from the mesenchyme. Even though they affect individuals in all age groups, the prevalence of subtypes of STSs changes significantly from childhood through adolescence into adulthood. The mainstay of therapy is surgery, with or without the addition of chemotherapy and/or radiation therapy. These treatment modalities are associated, in many cases, with significant morbidity and, given the heterogeneity of tumor histologies encompassed by the term “STS”, have not uniformly improved outcomes. Moreover, some subgroups of STSs appear to be more, and others less, responsive to conventional chemotherapy agents. Over the last two decades, our understanding of the biology of STSs is slowly increasing, allowing for the development of more targeted therapies. We review the new treatment modalities that have been tested on patients with STSs, with a special focus on adolescents and young adults, a group of patients that is often underrepresented in clinical trials and has not received the dedicated attention it deserves, given the significant differences in biology and treatment response in comparison to children and adults. Keywords: synovial sarcoma, MPNST, soft tissue sarcoma, targeted therapy |
topic |
synovial sarcoma MPNST soft tissue sarcoma targeted therapy |
url |
https://www.dovepress.com/targeted-therapy-for-soft-tissue-sarcomas-in-adolescents-and-young-adu-peer-reviewed-article-AHMT |
work_keys_str_mv |
AT steppanda targetedtherapyforsofttissuesarcomasinadolescentsandyoungadults AT pratilasca targetedtherapyforsofttissuesarcomasinadolescentsandyoungadults AT loebdm targetedtherapyforsofttissuesarcomasinadolescentsandyoungadults |
_version_ |
1716782685718839296 |